HRP20160531T1 - Dinukleotidni prolijekovi - Google Patents

Dinukleotidni prolijekovi Download PDF

Info

Publication number
HRP20160531T1
HRP20160531T1 HRP20160531TT HRP20160531T HRP20160531T1 HR P20160531 T1 HRP20160531 T1 HR P20160531T1 HR P20160531T T HRP20160531T T HR P20160531TT HR P20160531 T HRP20160531 T HR P20160531T HR P20160531 T1 HRP20160531 T1 HR P20160531T1
Authority
HR
Croatia
Prior art keywords
alkyl
aryl
image
formula
compound
Prior art date
Application number
HRP20160531TT
Other languages
English (en)
Croatian (hr)
Inventor
Radhakrishnan P. Iyer
Seetharamaiyer Padmanabhan
Original Assignee
Spring Bank Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bank Pharmaceuticals, Inc. filed Critical Spring Bank Pharmaceuticals, Inc.
Publication of HRP20160531T1 publication Critical patent/HRP20160531T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
HRP20160531TT 2005-12-13 2006-12-13 Dinukleotidni prolijekovi HRP20160531T1 (hr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US75003605P 2005-12-13 2005-12-13
US80029406P 2006-05-15 2006-05-15
US11/637,520 US8076303B2 (en) 2005-12-13 2006-12-12 Nucleotide and oligonucleotide prodrugs
PCT/US2006/047617 WO2007070598A2 (en) 2005-12-13 2006-12-13 Nucleotide and oligonucleotide prodrugs
EP06848625.7A EP1968612B1 (en) 2005-12-13 2006-12-13 Dinucleotide prodrugs

Publications (1)

Publication Number Publication Date
HRP20160531T1 true HRP20160531T1 (hr) 2016-08-12

Family

ID=38194676

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160531TT HRP20160531T1 (hr) 2005-12-13 2006-12-13 Dinukleotidni prolijekovi

Country Status (17)

Country Link
US (6) US8076303B2 (enExample)
EP (3) EP3553072A1 (enExample)
JP (1) JP5044854B2 (enExample)
KR (2) KR101123534B1 (enExample)
CN (2) CN102796155B (enExample)
CY (2) CY1117576T1 (enExample)
DK (2) DK1968612T3 (enExample)
ES (2) ES2573928T3 (enExample)
HR (1) HRP20160531T1 (enExample)
HU (2) HUE029190T2 (enExample)
IN (1) IN2015DN01786A (enExample)
LT (1) LT3090748T (enExample)
PL (2) PL1968612T3 (enExample)
PT (1) PT3090748T (enExample)
RS (1) RS54867B1 (enExample)
SI (2) SI1968612T1 (enExample)
WO (1) WO2007070598A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1365776B1 (en) * 2001-01-16 2005-04-13 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
EP2271351A4 (en) 2008-04-03 2016-08-31 Spring Bank Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
EP2346883B1 (en) * 2008-09-23 2016-03-23 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
RU2015151857A (ru) 2008-12-02 2019-01-15 Уэйв Лайф Сайенсес Джапан, Инк. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
EP2382227A1 (en) * 2008-12-23 2011-11-02 Girindus America, Inc. Sulfurizing reagents and their use for oligonucleotides synthesis
AU2015255202B2 (en) * 2009-07-06 2017-07-27 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods of use thereof
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
CN101659612B (zh) * 2009-09-24 2013-01-09 华润赛科药业有限责任公司 一种选择性酯化的方法
CN103298475A (zh) * 2010-08-30 2013-09-11 斯普林银行医药公司 作为治疗剂的寡核苷酸类似物的设计
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
KR101327026B1 (ko) 2011-11-29 2013-11-13 현대자동차주식회사 운전자 보호장치
CN104661664B (zh) 2012-07-13 2020-07-03 波涛生命科学有限公司 手性控制
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
CA2879023C (en) 2012-07-13 2017-03-28 Wave Life Sciences Japan Asymmetric auxiliary group
CN105992587A (zh) * 2013-02-18 2016-10-05 春堤制药公司 作为疫苗佐剂和治疗试剂的短寡核苷酸的设计
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
GB201403697D0 (en) * 2014-03-03 2014-04-16 Link Technologies Ltd Compounds and methods of use
EP3197459B1 (en) * 2014-09-28 2025-02-12 Huahui Health Ltd. Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport
WO2016164625A1 (en) * 2015-04-07 2016-10-13 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hcv infection
CN107922455A (zh) * 2015-07-02 2018-04-17 春季银行制药股份有限公司 用于治疗病毒感染的组合物和方法
EP3426671A4 (en) * 2016-03-11 2019-11-20 Spring Bank Pharmaceuticals, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
US20190292215A1 (en) * 2016-07-15 2019-09-26 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
JOP20170192A1 (ar) * 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
CN110467647B (zh) * 2018-05-09 2022-08-30 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物的制备方法
CN110467646A (zh) * 2018-05-09 2019-11-19 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物
WO2019219070A1 (zh) * 2018-05-18 2019-11-21 正大天晴药业集团股份有限公司 氘代的低聚核苷酸及前体药物
CN112512531B (zh) 2018-06-01 2024-04-09 卫材R&D管理有限公司 用于膀胱癌的治疗的方法
FR3082434B1 (fr) 2018-06-14 2021-04-30 Cairdac Implant cardiaque autonome de type "capsule leadless", comprenant un recuperateur d'energie a lame piezoelectrique
MX2020013322A (es) 2018-08-16 2021-02-22 Eisai R&D Man Co Ltd Sales de compuestos y cristales de los mismos.
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
JP2022509929A (ja) 2018-10-31 2022-01-25 ノバルティス アーゲー Ｓｔｉｎｇアゴニストを含むｄｃ－ｓｉｇｎ抗体コンジュゲート
WO2020114495A1 (zh) * 2018-12-06 2020-06-11 正大天晴药业集团股份有限公司 二核苷酸化合物及其前体药物
CN111484540B (zh) * 2019-01-25 2023-09-08 博瑞生物医药（苏州）股份有限公司 含双核苷酸结构的化合物
CN111484541B (zh) * 2019-01-25 2023-06-02 博瑞生物医药（苏州）股份有限公司 双核苷酸前体药物及其制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US688183A (en) 1900-12-17 1901-12-03 Carl C Lantz Adjusting-clip for garment-supporters.
DE2817041C2 (de) 1978-04-19 1987-02-19 Reich Spezialmaschinen GmbH, 7440 Nürtingen Vorrichtung zum Aufteilen von Platten
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
JPH05506033A (ja) 1990-04-18 1993-09-02 ノーウィッチ、イートン、ファーマスーティカルズ、インコーポレーテッド 抗微生物性キノロニルラクタム類
US5444063A (en) 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5432165A (en) 1992-04-06 1995-07-11 Oclassen Pharmaceuticals, Inc. Methods for the treatment of infection caused by Hepatitis B virus (HBV)
FR2705099B1 (fr) * 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
US5955591A (en) * 1993-05-12 1999-09-21 Imbach; Jean-Louis Phosphotriester oligonucleotides, amidites and method of preparation
FR2709754B1 (fr) 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
US5587362A (en) 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5581639A (en) 1995-05-04 1996-12-03 National Research Council Of Canada Raman-nath diffraction grating
AU4156197A (en) 1996-08-21 1998-03-06 Hybridon, Inc. Oligonucleotide prodrugs
AU4988697A (en) 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
US6444652B1 (en) 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CA2599597A1 (en) 1998-08-10 2000-02-24 Idenix (Cayman) Limited .beta.-l-2'-deoxy-nucleosides for the treatment of hepatitis b
WO2000009531A2 (en) 1998-08-10 2000-02-24 Novirio Pharmaceuticals Limited β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
US6875751B2 (en) 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP2682397B1 (en) 2000-07-21 2017-04-19 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
JP2005525991A (ja) * 2001-05-16 2005-09-02 マイジェニックス インコーポレイテッド 核酸ベースの化合物およびその使用方法
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN101146337B (zh) 2006-09-15 2011-04-20 华为技术有限公司 新接入节点随机接入的方法及其系统
EP2271351A4 (en) * 2008-04-03 2016-08-31 Spring Bank Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS

Also Published As

Publication number Publication date
ES2729657T3 (es) 2019-11-05
CN101437397A (zh) 2009-05-20
KR20080072084A (ko) 2008-08-05
HUE029190T2 (en) 2017-02-28
PL3090748T3 (pl) 2020-03-31
CN102796155B (zh) 2015-08-26
EP1968612A2 (en) 2008-09-17
IN2015DN01786A (enExample) 2015-07-10
EP3090748B1 (en) 2019-02-20
CY1117576T1 (el) 2017-04-26
PT3090748T (pt) 2019-06-04
WO2007070598A2 (en) 2007-06-21
KR101123534B1 (ko) 2012-03-13
ES2573928T3 (es) 2016-06-13
US10047114B2 (en) 2018-08-14
CN102796155A (zh) 2012-11-28
US8076303B2 (en) 2011-12-13
US20120264709A1 (en) 2012-10-18
SI1968612T1 (sl) 2016-10-28
US20180273574A1 (en) 2018-09-27
EP1968612B1 (en) 2016-03-09
CN101437397B (zh) 2012-09-05
WO2007070598A8 (en) 2008-12-31
US20140323554A1 (en) 2014-10-30
US20160060287A1 (en) 2016-03-03
SI3090748T1 (sl) 2019-09-30
JP2009519345A (ja) 2009-05-14
HUE044034T2 (hu) 2019-09-30
KR20110125677A (ko) 2011-11-21
WO2007070598A9 (en) 2007-11-08
DK1968612T3 (en) 2017-05-22
US20200087338A1 (en) 2020-03-19
US10344046B2 (en) 2019-07-09
CY1121639T1 (el) 2020-07-31
WO2007070598A3 (en) 2008-10-30
EP1968612A4 (en) 2013-01-09
EP3553072A1 (en) 2019-10-16
JP5044854B2 (ja) 2012-10-10
DK3090748T3 (da) 2019-05-27
US8691787B2 (en) 2014-04-08
LT3090748T (lt) 2019-08-26
US20070149462A1 (en) 2007-06-28
PL1968612T3 (pl) 2016-11-30
RS54867B1 (sr) 2016-10-31
EP3090748A1 (en) 2016-11-09
KR101248873B1 (ko) 2013-04-02

Similar Documents

Publication Publication Date Title
HRP20160531T1 (hr) Dinukleotidni prolijekovi
NZ597544A (en) Modified 4'-nucleosides as antiviral agents
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
MX2009012433A (es) Azido nucleosidos de purina para el tratamiento de infecciones virales.
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
BRPI0414111A (pt) inibidores heterocìclicos de mek e métodos de uso dos mesmos
ATE512973T1 (de) Nukleosid-arylphosphoramidate und ihre verwendung als antivirale mittel zur behandlung von hepatitis-c-virus
TW200600096A (en) Prodrugs of piperazine and substituted piperidine antiviral agents
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
TW200500341A (en) Novel compounds
SG10201809895YA (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
MY145460A (en) Biaryl ether urea compounds
HRP20151075T1 (hr) Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino) propanoat
ATE499835T1 (de) Fungizide n-cycloalkyl-benzyl-thiocarboxamide oder n-cycloalkyl-benzyl-n'-substituierte amidin- derivate
MXPA05006798A (es) Ligandos de adenina nucleotido translocasa (ant) y composiciones y metodos relacionados a estos.
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
EA200500846A1 (ru) Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации
TW200630344A (en) Tetracyclic indole derivatives as antiviral agents
MY143400A (en) 2-pyridone derivatives as neutrophil elastase inhibitors and their use
RU2651892C3 (ru) Нуклеозидфосфорамидаты в качестве противовирусных агентов
TW200745067A (en) Novel compounds
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft